Anti-β2 glycoprotein I antibodies and pregnancy outcome in antiphospholipid syndrome


  • The authors have stated explicitly that there are no conflicts of interest in connection with this article.


Fufan Zhu, Department of Obstetrics and Gynecology, Second Xiangya Hospital, 139 Middle Renmin Road, Changsha, Hunan 410011, China. E-mail:


The relation between pregnancy outcome and single- or double-positivity of anticardiolipin (aCL) and β2 glycoprotein I (aβ2GPI) in antiphospholipid syndrome (APS) has yet to be clearly documented. In this article, a total of 191 lupus anticoagulant-negative pregnant women with primary APS were retrospectively divided into three groups: aCL+/aβ2GPI; aCL+/aβ2GPI+; aCL/aβ2GPI+. All women had received medical therapy consisting of prednisone (10–15 mg/day), low-dose aspirin (50 mg/day), and low molecular weight heparin (40 mg/day). The miscarriage rate in the double-positive group was significantly higher than that in the aCL+/aβ2GPI group (46.2% vs. 22.1%, < 0.05); the miscarriage rate in the aCL/aβ2GPI+ group (36.4%) was not significantly different from the rates of the other two groups (> 0.05). Thus, double-positivity may be a risk factor for pregnancy loss and aβ2GPI antibody may be a better prognostic marker than aCL antibody for pregnancy outcome.